MS
REGN icon

Marshall & Sullivan’s Regeneron Pharmaceuticals REGN Stock Holding History

Marshall & Sullivan’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-100
Closed -$49K – 61
2016
Q1 		$49K Hold
100
– – 0.06% 46
2015
Q4 		$49K Hold
100
– – 0.06% 46
2015
Q3 		$49K Buy
+100
New +$53.7K 0.06% 46

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Marshall & Sullivan's REGN Position: Q2 2016 in Review

Marshall & Sullivan sold out of Regeneron Pharmaceuticals (REGN) in Q2 2016, closing a stake of 100 shares — an estimated $49K sold.

Marshall & Sullivan first reported a position in REGN in Q3 2015 and held it in 3 quarters. The position peaked at $49K in Q1 2016. 542 funds tracked by Wall St. Rank hold REGN as of Q2 2016.

  • Marshall & Sullivan reported no remaining Regeneron Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Marshall & Sullivan sold 100 Regeneron Pharmaceuticals shares in Q2 2016, an estimated $49K.
  • Marshall & Sullivan first reported a position in Regeneron Pharmaceuticals in Q3 2015 and held it in 3 quarters.
  • Marshall & Sullivan's Regeneron Pharmaceuticals position peaked at $49K in Q1 2016.
  • 542 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2016.

Based on Marshall & Sullivan's 13F filing for Q2 2016, filed 12 Aug 2016.